Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

3.5K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Overview of Cell-Matrix Interactions01:24

Overview of Cell-Matrix Interactions

9.5K
The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...
9.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.2K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosing intravascular B-cell lymphoma using nanopore sequencing of cell-free DNA from cerebrospinal fluid.

ESMO open·2024
Same author

High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT.

ESMO open·2024
Same author

Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis.

ESMO open·2024
Same author

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.

British journal of cancer·2024
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same author

Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - A monocentric analysis.

British journal of haematology·2023
Same journal

PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction.

Nature communications·2026
Same journal

PfApiAT2 is a proline transporter essential for the transmission of Plasmodium falciparum by the mosquito vector.

Nature communications·2026
Same journal

Transient distortions of the South Atlantic Anomaly radiation environments driven by electric fields.

Nature communications·2026
Same journal

Structural basis of the regulation by CDK11 kinase of early spliceosome activation and evidence for its proofreading by DHX15 helicase.

Nature communications·2026
Same journal

Structural and mechanistic insights into primer synthesis initiation by DNA primase.

Nature communications·2026
Same journal

Changes in heritability and shared environmentality of educational attainment across twentieth-century Norway.

Nature communications·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl
05:20

A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl

Published on: November 28, 2014

13.9K

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.

M Wroblewski1,2, R Bauer1,2, M Cubas Córdova1,2

  • 1Department of Hematology and Oncology with Sections BMT and Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.

Nature Communications
|August 18, 2017
PubMed
Summary
This summary is machine-generated.

Mast cells drive resistance to anti-angiogenic therapy by promoting endothelial cell proliferation. Targeting mast cells, for example with cromolyn, sensitizes tumors to this therapy, improving treatment efficacy.

More Related Videos

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

12.9K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

2.1K

Related Experiment Videos

Last Updated: Feb 24, 2026

A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl
05:20

A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl

Published on: November 28, 2014

13.9K
Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

12.9K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

2.1K

Area of Science:

  • Oncology
  • Immunology
  • Vascular Biology

Background:

  • VEGF-targeted anti-angiogenic therapies face significant clinical resistance.
  • Endothelial cell proliferation and organization are key factors in tumor angiogenesis.

Purpose of the Study:

  • To investigate the role of mast cells in mediating resistance to VEGF-centered anti-angiogenic therapy.
  • To explore therapeutic strategies targeting mast cells to enhance anti-angiogenic treatment efficacy.

Main Methods:

  • Utilized various tumor models to assess the impact of mast cells on anti-angiogenic therapy efficacy.
  • Analyzed mast cell degranulation, cytokine/granzyme B secretion, and their effects on endothelial cells.
  • Investigated the role of FGF-1, GM-CSF, and FGF-2 in therapy resistance.
  • Evaluated the efficacy of mast cell inhibition (cromolyn) in combination with anti-angiogenic therapy.

Main Results:

  • Absence of mast cells sensitized tumor vessels to anti-angiogenic therapy.
  • Mast cells secrete granzyme B, mobilizing FGF-1 and GM-CSF, and also secrete FGF-2, promoting angiogenesis.
  • These factors counteract anti-angiogenic therapy by reinducing endothelial cell proliferation.
  • Inhibition of mast cell degranulation with cromolyn improved anti-angiogenic therapy efficacy.

Conclusions:

  • Mast cells are critical mediators of resistance to VEGF-targeted anti-angiogenic therapy.
  • Targeting mast cell degranulation and their secreted factors presents a promising strategy to overcome therapy resistance.
  • Concomitant targeting of mast cells could significantly improve clinical outcomes for anti-angiogenic therapies.